QURE_OUT_1 [2025-04-17 09:37:24 -0400] 4189 Bytes | 1152 tokens | Cum: 1152 tkns (14.40% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at uniQure N.V. (QURE) which is at 13.2850 up from 9.3900. So, I pulled together a bunch of data for you to look over real fast. It's still early, 9:37:23 AM on Thu Apr 17, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: uniQure N.V. (QURE)
IPO: 2014-02-05 (11 Years Ago)
Market Cap: $467,765,012
Shares Outstanding: 54,080,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Here’s a list of headlines for uniQure N.V.:

Today 07:17AM - uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
Mar-30-25 07:10AM - abrdn World Healthcare Fund Q4 2024 Commentary
Mar-30-25 07:10AM 03:50AM - abrdn Life Sciences Investors Q4 2024 Commentary
Mar-30-25 07:10AM 02:50AM - abrdn Healthcare Investors Q4 2024 Commentary
Feb-27-25 08:35AM - UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Feb-27-25 08:35AM 07:05AM - uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
Feb-07-25 01:04PM - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Feb-07-25 01:04PM 09:12AM - CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-07T14:12:00Z - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
B2 - 2025-01-07T21:49:00Z - uniQure Announces Proposed Public Offering
B3 - 2024-08-30T12:59:00Z - Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology
B4 - 2024-07-10T12:01:12Z - Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
B5 - 2024-07-09T16:11:44Z - Crude Oil Down 1%; Soligenix Shares Surge - Helen Of Troy (NASDAQ:HELE) - Benzinga
B6 - 2024-07-09T11:06:54Z - uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of ... - GlobeNewswire

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for uniQure N.V. (QURE).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

QURE_OUT_3 [2025-04-17 09:37:25 -0400] 885 Bytes | 248 tokens | Cum: 1402 tkns (17.52% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/02/n43560239/csl-behrings-gene-therapy-hemgenix-etranacogene-dezaparvovec-drlb-four-years-post-infusion-data-coCSL Behring's gene therapy HEMGENIX has shown sustained efficacy and safety in treating adults with hemophilia B, with 94% of patients remaining free of continuous prophylaxis treatment four years after a single infusion.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_5 [2025-04-17 09:37:25 -0400] 972 Bytes | 268 tokens | Cum: 1672 tkns (20.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T11:56:06Z - uniQure shares soar on FDA breakthrough therapy designation By Investing.com...
A2 - 2025-04-17T11:56:06Z - uniQure shares soar on FDA breakthrough therapy designation By Investing.com...
A3 - 2025-04-17T11:41:57Z - uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Hunti...
A4 - 2025-04-17T11:44:18Z - uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Hunti...
A5 - 2025-04-17T11:22:12Z - FDA grants breakthrough status to uniQure's Huntington's therapy By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

QURE_OUT_7 [2025-04-17 09:37:26 -0400] 1181 Bytes | 295 tokens | Cum: 1969 tkns (24.61% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**uniQure shares soar on FDA breakthrough therapy designation By Investing.com**Date: 2025-04-17Source: {'uri': 'za.investing.com', 'dataType': 'news', 'title': 'Investing.com South Africa'}URL: https://za.investing.com/news/stock-market-news/uniqure-shares-soar-on-fda-breakthrough-therapy-designation-93CH-3662289Investing.com -- Shares of uniQure N.V. (NASDAQ:QURE) surged 39% following the announcement that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to AMT-130, its gene therapy candidate for the treatment of Huntington's disease. This significant regulatory milestone, which aims to expedite the development and review process of AMT-130, has been well-received by investors, signaling potential for an accelerated path to market for the treatment.

The FDA's Breakthrough Therapy designation is supported by clinical data from ongoing Phase I/II

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_9 [2025-04-17 09:37:27 -0400] 1181 Bytes | 259 tokens | Cum: 2230 tkns (27.88% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): trials, which have indicated that AMT-130 could slow disease progression. The optimism surrounding uniQure's stock is further bolstered by a comprehensive set of FDA designations for AMT-130, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations, reflecting the drug's potential to address the urgent need for effective treatments for Huntington's disease.

uniQure's Chief Medical (TASE:BLWV) Officer, Walid Abi-Saab, M.D., highlighted the significance of the designation, stating, "Receiving Breakthrough Therapy designation underscores both the urgent need for effective treatments for Huntington's disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression." He expressed gratitude for the FDA's commitment to advancing gene therapies for patients with critical unmet needs and conveyed the compan

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_11 [2025-04-17 09:37:28 -0400] 921 Bytes | 200 tokens | Cum: 2432 tkns (30.40% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): y's eagerness to work with the agency to deliver AMT-130 to patients as swiftly as possible.

Huntington's disease is a debilitating neurodegenerative disorder characterized by motor symptoms, behavioral abnormalities, and cognitive decline, resulting in progressive deterioration. The disease affects approximately 70,000 people in the U.S. and Europe, with no current disease-modifying therapies available. The Breakthrough Therapy designation is particularly significant for uniQure, as it indicates that AMT-130 may offer substantial improvement over existing therapies for a serious condition, based on preliminary clinical evidence.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_13 [2025-04-17 09:37:30 -0400] 1078 Bytes | 285 tokens | Cum: 2719 tkns (33.99% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-02-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following Mgts Discussion and Analysis of Fin Cond and Results of Oper (MDA) is intended to help the reader understand our results of operations and financi...

S6 - 2025-02-27 8-K Item 2.02

Results of Oper and Fin Cond.

On February 27, 2025, uniQure N.V. (the Company ) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024 and highlighting Company progress. A copy of the press rele...

S9 - 2025-01-08 8-K Item1.01. Entry Into a Material Definitive Agrmt.

On January 7, 2025, uniQure N.V. (the Company) entered into an underwriting agreement (the Underwriting Agrmt) with Leerink Partners LLC, as representative of the several underwriters named therein (the Underwriters), re...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QURE_OUT_15 [2025-04-17 09:37:31 -0400] 1181 Bytes | 251 tokens | Cum: 2972 tkns (37.15% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following Managements Discussion and Analysis of Financial Condition and Results of Operations (MDA) is intended to help the reader understand our results of operations and financial condition. This MDA is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes thereto and other disclosures included in this Annual Report on Form 10-K, including the disclosures under Risk Factors. Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. (U.S. GAAP) and unless otherwise indicated are presented in U.S. dollars.

Except for the historical information contained herein, the matters discussed in this MDA may be deemed to be forward-looki

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_17 [2025-04-17 09:37:32 -0400] 1181 Bytes | 237 tokens | Cum: 3211 tkns (40.14% of 8k)
==========================================================================

Showing S5 (chunk 2 of 6): ng statements. Forward-looking statement are only predictions based on managements current views and assumptions and involve risks and uncertainties, and actual results could differ materially from those projected or implied. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as may, expect, anticipate, estimate, intend, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

Overview

We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_19 [2025-04-17 09:37:33 -0400] 1181 Bytes | 285 tokens | Cum: 3498 tkns (43.73% of 8k)
==========================================================================

Showing S5 (chunk 3 of 6): linical candidates for the treatment of Huntingtons disease, amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1, refractory mesial temporal lobe epilepsy (mTLE), and Fabry disease.

Huntingtons disease program (AMT-130)

AMT-130 is our novel gene therapy candidate for the treatment of Huntingtons disease, which utilizes our proprietary, gene-silencing miQURE platform and incorporates an AAV vector carrying a micro ribonucleic acid (miRNA) specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.

We are currently conducting the U.S. and European studies. We completed the enrollment of all 26 patients in the first two cohorts of our US study in March 2022 and the enrollment of 13 patients in the two cohorts of our European study in June 2023. As of February 2025, we have enrolled 12 patients into a third cohor

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_21 [2025-04-17 09:37:33 -0400] 1181 Bytes | 293 tokens | Cum: 3793 tkns (47.41% of 8k)
==========================================================================

Showing S5 (chunk 4 of 6): t to further investigate both doses of AMT-130 together with perioperative immunosuppression using the current, established stereotactic administration procedure.

RMAT Designation

In June 2024, we announced that the FDA granted us RMAT designation for AMT-130.

Updated Interim Data

In July 2024, we announced updated interim clinical data, including up to 24 months of follow-up data from 29 patients enrolled in the U.S. study and the European study as of a March 31, 2024 cut-off date.

Regulatory Alignment

In December 2024, following our initial Type B meeting, we announced that we had reached agreement with FDA on key elements of an accelerated approval pathway for AMT-130.

Other clinical candidates

In November 2024, we announced that the that the first patient was dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mTLE. In addition, th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_23 [2025-04-17 09:37:34 -0400] 1181 Bytes | 278 tokens | Cum: 4073 tkns (50.91% of 8k)
==========================================================================

Showing S5 (chunk 5 of 6): e FDA recently approved a protocol amendment expanding the inclusion criteria for certain patients in the first cohort to include patients with non-lesional mesial temporal lobe epilepsy in the non-dominant hemisphere.

In August 2024, we announced that the first patient was dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease. In February 2025, we announced that we completed the enrollment of the first cohort of the clinical trial and that we would proceed enrolling the second cohort of the clinical trial.

In October 2024, we announced the first patient was dosed in a Phase I/IIa clinical trial of AMT-162 for the treatment of SOD1-ALS. In January 2025, we announced that we completed the enrollment of the first cohort of the clinical trial and that we would proceed enrolling the second cohort of the clinical trial.

Sale of commercial manufacturing activi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_25 [2025-04-17 09:37:37 -0400] 790 Bytes | 182 tokens | Cum: 4257 tkns (53.21% of 8k)
==========================================================================

Showing S5 (chunk 6 of 6): ties

In June 2024, we and Genezen entered into the Lexington Transaction, which closed in July 2024. Genezen acquired manufacturing facility including equipment and related manufacturing operations with a carrying value of $15.2 million, inventory with a carrying value of $8.8 million and certain other assets (including allocated goodwill) with a carrying value of $2.8 million associated with the Lexington Facility on Closing.

As consideration for the Lexington Transaction, we received from Genez...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

QURE_OUT_27 [2025-04-17 09:37:45 -0400] 9493 Bytes | 2443 tokens | Cum: 6702 tkns (83.78% of 8k)
==========================================================================

This is our set of metrics for uniQure N.V..
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 0 | Perf Month: -29.45% | Option/Short: Yes / Yes | Sales Y/Y TTM: 71.17% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.10M | Perf Quarter: -32.88% | Short Float: 8.88% | ROE: -238.46% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 4.00 | ROI: -48.83% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 40.27 | Market Cap: 507.78M | Short Interest: 4.39M | Sales Surprise: -70.90% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 1.11 | Shs Outstand: 54.08M | Beta: 0.21 | EPS Surprise: -128.21% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -13.78% | Shs Float: 49.50M | Sales Q/Q: -21.95% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -23.11% | Inst Own: 76.45% | Sales past 5Y: 323.68% | Earnings: Feb 27 BMO |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -2.28% | Insider Own: 8.47% | Employees: 209 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 2.51% | Insider Trans: -4.25% | Debt/Eq: - | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by uniQure N.V. officers or majority shareholders (if available).

Inside Trans: uniQure N.V. (QURE) by Potts Jeannette (Chief Legal Officer) on 2025-03-03
- Ordinary Shares: 35000 shares at $0 (D)
- Ordinary Shares: 7076 shares at $10.29 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Stock Option (Right to Buy): 60000 shares at $0 (D)

Inside Trans: uniQure N.V. (QURE) by KLEMT CHRISTIAN (Chief Financial Officer) on 2025-03-03
- Ordinary Shares: 73000 shares at $0 (D)
- Ordinary Shares: 10438 shares at $10.29 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Stock Option (Right to Buy): 126000 shares at $0 (D)

Inside Trans: uniQure N.V. (QURE) by Abi-Saab Walid (Chief Medical Officer) on 2025-03-03
- Ordinary Shares: 38000 shares at $0 (D)
- Ordinary Shares: 1350 shares at $10.29 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Stock Option (Right to Buy): 66000 shares at $0 (D)

Inside Trans: uniQure N.V. (QURE) by Kapusta Matthew C (CEO, Managing Director) on 2025-03-03
- Ordinary Shares: 99000 shares at $0 (D)
- Ordinary Shares: 28341 shares at $10.29 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Stock Option (Right to Buy): 171000 shares at $0 (D)

Inside Trans: uniQure N.V. (QURE) by KLEMT CHRISTIAN (Chief Financial Officer) on 2025-02-25
- Ordinary Shares: 14341 shares at $10.7 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Ordinary Shares: 5712 shares at $0 (D)
- Ordinary Shares: 2916 shares at $11.32 (D) Footnote: The shares were sold upon the vesting of PRSUs solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Performance Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.

Inside Trans: uniQure N.V. (QURE) by Kapusta Matthew C (CEO, Managing Director) on 2025-02-25
- Ordinary Shares: 26727 shares at $10.7 (D) Footnote: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- Ordinary Shares: 16324 shares at $0 (D)
- Ordinary Shares: 6717 shares at $11.32 (D) Footnote: The shares were sold upon the vesting of PRSUs solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Performance Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 28587000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -239501000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 13.179
Average Volume: 1582661.52
30-Day High: 14.77
30-Day Low: 8.34

[Detailed Financials: Q3 2024]
- Total Assets: $645,806,000.0
- Total Liabilities: $589,985,000.0
- Total Equity: $55,821,000.0
- Current Assets: $464,138,000.0
- Current Liabilities: $71,273,000.0

[Income Statement: Q3 2024]
- Revenue: $2,287,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.91

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-37,960,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $730,846,000.0
- Total Liabilities: $633,739,000.0
- Total Equity: $97,107,000.0
- Current Assets: $591,968,000.0
- Current Liabilities: $80,468,000.0

[Income Statement: Q2 2024]
- Revenue: $11,126,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.16

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $44,770,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of uniQure N.V. (QURE).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about uniQure N.V..

2) MARKET_SCORE[]
This conversation was initiated because QURE is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for QURE.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, QURE could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect QURE to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of uniQure N.V..

11) ETHICAL_RATING[]
Rate uniQure N.V.’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of uniQure N.V..
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

QURE_IN_29 [2025-04-17 09:37:46 -0400] 126 Bytes | 29 tokens | Cum: 6964 tkns (87.05% of 8k)
==========================================================================

====================================
[2025-04-17 09:37:46] # Analysis Completed
Elapsed Time: 22.65 seconds